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Summary
The nature of dendritic cell(s) (DC[s]) that conditions
efficient in vivo priming of CD8+ CTL after immuniza-
tion via epithelial tissues remains largely unknown.
Here, we show that myeloid DCs rapidly recruited by
adjuvants into the buccal mucosa or skin are essential
for CD8+ T cell crosspriming. Recruitment of circulat-
ing DC precursors, including Gr1+ monocytes, pre-
cedes the sequential accumulation of CD11c+ MHC
class II+ DCs in dermis and epithelium via a CCR6/
CCL20-dependent mechanism. Remarkably, a defect
in CCR6, local neutralization of CCL20, or depletion
of monocytes prevents in vivo priming of CD8+ CTL
against an innocuous protein antigen administered
with adjuvant. In addition, transfer of CCR6-sufficient
Gr1+ monocytes restores CD8+ T cell priming in CCR6º/º
mice via a direct Ag presentation mechanism. Thus,
newly recruited DCs likely derived from circulating
monocytes are responsible for efficient crosspriming
of CD8+ CTL after mucosal or skin immunization.
Introduction
DCs are professional APCs with the unique property of
inducing priming and differentiation of naive CD4+ and
CD8+ T cells into helper T cells and cytotoxic effectors,
*Correspondence: dubois@cervi-lyon.inserm.fr (B.D.); kaiserlian@
cervi-lyon.inserm.fr (D.K.)respectively. Langerhans cells (LCs), the prototype of
immature DCs residing in pluri-stratified epithelia of
skin, buccal mucosa, and vagina, are sentinels special-
ized in the uptake and sampling of tissue antigens (Ag),
which they transport via afferent lymph to draining lymph
nodes (LN) for presentation to T cells (Banchereau and
Steinman, 1998). Under steady-state conditions, resi-
dent LCs migrate continuously at a low rate to draining
LN, presumably to induce or maintain tolerance to self
or innocuous antigens. Danger signals provided by a
variety of stimuli, such as microbial compounds activat-
ing Toll-like receptors and contact-sensitizing haptens
that induce local release of inflammatory cytokines
and chemokines, trigger DC maturation. This complex
DC maturation process is characterized by an increased
expression of cell-surface MHC/peptide complexes and
costimulatory molecules associated with an enhanced
rate of migration to the T cell area of draining lymph
nodes, where DCs become mature antigen-presenting
DCs able to activate naive T cells and initiate their dif-
ferentiation into functional effectors. It is becoming in-
creasingly clear that DCs of lymphoid organs comprise
various subsets that likely differ in their relative ability
to prime functionally distinct CD4+ or CD8+ effector
T cells (reviewed in Heath et al., 2004; Itano and Jenkins,
2003).
However, the contribution of DCs residing in mucosae
and skin in priming of specific effector T cells remains
largely debated. Two studies with in vivo models of ep-
ithelial HSV infection argued against a role for LC in di-
rect priming of protective antiviral-specific T cells (Allan
et al., 2003; Zhao et al., 2003). In addition, LCs were re-
cently shown to be dispensable for priming effector cells
of contact sensitivity, a prototype of Ag-specific T cell-
mediated skin inflammatory response (Bennett et al.,
2005; Kaplan et al., 2005; Kissenpfennig et al., 2005).
The prevailing correlate of these findings—that dermal or
submucosal DC might be instrumental for inducing T cell
priming after mucosal or cutaneous immunization—has
received some support (Belz et al., 2004; Itano et al.,
2003; Zhao et al., 2003). Besides these epithelial tissue
resident DCs, we and others have observed that DCs
are rapidly recruited into muco-cutaneous tissues by
proinflammatory stimuli from bacteria and virus (McWil-
liam et al., 1996; Zhao et al., 2003), soluble Ag, such as
haptens (Desvignes et al., 1998) and viral proteins (Etch-
art et al., 2001), or mucosal adjuvants such as Cholera
toxin (CT) (Anjuere et al., 2004). Remarkably, delivery
of the hapten 2-4 dinitrofluorobenzene (DNFB) (Des-
vignes et al., 1998) or measles virus nucleoprotein (NP)
(Etchart et al., 2001) through the skin or buccal mucosa
generated in vivo priming of specific CD8+ CTL. This
suggested that these two proinflammatory immunogens
had intrinsic adjuvant properties that may be mediated
by their ability to induce DC recruitment. Along these
lines, in vivo studies revealed that monocytes can be
recruited from peripheral blood at sites of inflammation
and could differentiate locally into MHC class IIhigh
CD11clow DCs (Randolph et al., 1999). However, how
these cells are recruited and whether they play a role
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to resident DC, remains largely unknown.
Monocyte chemotactic proteins, CCL20/MIP-3a, and
other chemokines have been reported to attract imma-
ture DCs in vitro (reviewed in Dieu-Nosjean et al.,
1999). CCL20, produced by epithelial cells of inflamed
epithelial tissues (reviewed in Schutyser et al., 2003), is
the most potent chemokine for selective attraction of
epidermal LC in vitro via interaction with the CCR6 re-
ceptor (Charbonnier et al., 1999; Dieu-Nosjean et al.,
2000) and might be responsible for DC accumulation in
psoriatic lesional skin (Dieu-Nosjean et al., 2000). Be-
sides, CCR6º/º mice exhibit impaired humoral immune
response to orally administered Ag and to enteropathic
rotavirus infection (Cook et al., 2000). However, in vivo
evidence in relevant patho-physiological situations for
a role for CCR6/CCL20 chemokine receptor/ligand inter-
action in DC recruitment in skin or mucosal tissues has
been scarcely documented (Merad et al., 2004).
In this study, we investigated the mechanism and
functional outcome of adjuvant-dependent DC recruit-
ment into pluri-stratified epithelial tissues. Our findings
demonstrate that freshly recruited DCs derived from cir-
culating monocytes are responsible for efficient priming
of CD8+ CTL effectors after mucosal or skin immuniza-
tion with a soluble protein Ag.
Results
DCs Transiently Accumulate in Dermis
and Epithelium at the Site of Immunization
with DNFB or NP
We previously documented that the hapten DNFB and
measles virus NP are two potent immunogens that share
the ability to induce specific CD8+ CTL without CD4+
T cell help, after transepithelial delivery via the skin or
buccal mucosa, two pluristratified epithelial tissues
that exhibit a similar anatomical distribution of DC, in-
cluding LC (Desvignes et al., 1998; Etchart et al., 2001).
Topical DNFB delivery onto the buccal mucosa gener-
ated, within 2 to 6 hr, a transient local inflammatory reac-
tion characterized by enlarged blood vessels and
edema of the lamina propria (i.e., dermis) with mononu-
clear cell infiltrates extending to the underlying muscle
layer (Figures 1A and 1B, left panel). Buccal NP immuni-
zation generated a milder local inflammatory reaction
with only focal mononuclear cell infiltration of dermal pa-
pillae (Figures 1C and 1D, left panel). DNFB or NP deliv-
ery onto the buccal mucosa (Figures 1A–1D) or skin
(data not shown) induced, within 6 hr, a transient accu-
mulation of MHC class II+ cells at the site of immuniza-
tion, confirming our previous results (Desvignes et al.,
1998; Etchart et al., 2001). Staining with anti-CD11c or
anti-CD11b Abs revealed that part of the MHC II+ cells
that accumulate after immunization represented bona
fide myeloid CD11c+ DCs (Figures 1A–1D). An immuno-
histochemical analysis of buccal mucosa at various times
after DNFB painting revealed a rapid accumulation of
MHC II+ cells in the lamina propria with a subsequent in-
crease in the number of epithelial LCs as assessed by a
staining for Langerin (Valladeauetal., 2002,2000) (Figures
1E and 1F). Kinetics analysis of MHC class II+ DCs and of
Langerin+ cells, accumulating in the dermis and the epi-thelium, respectively, showed that the density of MHC
class II+ DCs at the dermo-epithelial junction was twice
higher between 2 to 6 hr after immunization, whereas
the number of LCs gradually increased between 2 and 6
hr (Figure 1G). Both dermal DC and epithelial LC numbers
returned tosteady-state levelsby24 hr, reminiscent to the
kinetics of DC migration to draining LN (Ruedl et al., 2000).
These data demonstrate that transepithelial delivery
of proinflammatory Ag, such as DNFB and NP, promotes
sequential accumulation of bona fide DCs into the dermis
and the epithelium.
Recruitment of Circulating DC Precursors
Contributes to DNFB-Induced Local
LC Accumulation
Accumulation of DC at the site of immunization may re-
sult from the attraction of resident cells migrating from
adjacent areas and/or recruitment of circulating DCs
or DC precursors. Monocytes constitute the most abun-
dant source of blood DC precursors and, in response to
inflammatory stimuli, can migrate into the skin where
they differentiate into DCs (Qu et al., 2004; Randolph
et al., 1999). Analysis of skin epithelial cell suspensions
revealed that topical delivery of DNFB induced the re-
cruitment of CD11b+Gr1high cells and CD11b+Gr1+/low
cells (Figure 2A), corresponding to neutrophils and
monocytes, respectively (Lagasse and Weissman,
1996). Thus, DNFB delivery rapidly mobilizes circulating
Gr1+ monocytes to the skin.
We next analyzed the contribution of circulating DC
precursors to the accumulation of LCs. To this end, we
exploited a model of bone marrow chimeras in which,
at steady-state, tissue resident (radioresistant) LCs
remain of recipient origin, whereas other DCs and DC
precursors are replaced by donor bone marrow cells
(Merad et al., 2002). This offers a unique opportunity to
determine whether DNFB-recruited LCs derive from cir-
culating donor DC precursors. CD45.1 mice were lethally
irradiated and reconstituted with bone marrow cells from
congenic CD45.2 mice (CD45.2/CD45.1 bone marrow
chimeras). Eight weeks after the bone marrow transfer,
the vast majority of MHC II+ LC in skin epithelial sheets
were still of recipient origin (e.g., CD45.1+, Figure 2B),
in accordance with previous reports (Allan et al., 2003;
Merad et al., 2002). In contrast, blood myeloid cells and
most dermal DCs were derived from the bone marrow
transplant (e.g., CD45.2+). Interestingly, the proportion
of skin LC expressing the donor CD45.2 marker in-
creased by more than 2-fold 6 hr after DNFB painting
(Figure 2B). In light of the sequential accumulation of
MCH-II+ cells into the dermis and epithelium, these re-
sults demonstrate that recruitment of circulating DC pre-
cursors contributes to LC accumulation at the site of
DNFB immunization.
Critical Role of CCR6/CCL20 in DC Accumulation
into Epithelial Tissues
CCL20 is the major chemokine that attracts LC and LC-
precursors and has been proposed to induce LC recruit-
ment at sites of inflammation (Dieu-Nosjean et al., 2000;
Merad et al., 2004). Thus, we examined whether buccal
delivery of DNFB or NP triggered local CCL20 produc-
tion. Reverse-transcriptase-polymerase chain reaction
(RT-PCR) analysis revealed that CCL20 transcripts,
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193Figure 1. Immunohistochemical Analysis of DC Accumulation Induced by Buccal Immunization with DNFB or NP
(A–D) HPS staining and staining for MHC class II, CD11c, CD11b, or Langerin molecules were conducted on cryostat sections of buccal mucosa
two hr after mucosal delivery of either vehicle (A), DNFB (B), PBS (C), or NP (D). Final magnification is3400. Ep, epithelium; dotted line, basement
membrane; arrow, blood vessel.
(E–G) Staining for MHC class II (E) or Langerin molecules (F) was carried out at 2, 6, and 24 hr after topical application of DNFB or vehicle alone
(2 hr) onto the buccal mucosa.
(G) The density of MHC class II+ cells in the lamina propria and of Langerin+ cells in the epithelium is expressed as the number of positive cells per
square millimeter of tissue. Each dot represents the mean of four fields in four sections of buccal mucosa; each histogram bar represents the
mean values obtained for three mice per group. The asterisk indicates p < 0.01; NS, not significant.expressed constitutively at variable interindividual
levels, were dramatically upregulated as early as 30
min to 2 hr after NP (Figure 3A) or DNFB (Figure 3B) im-
munization. Skin painting with DNFB similarly upregu-
lated local CCL20 production (not shown).
Because CCR6 is the only receptor for CCL20 (Cook
et al., 2000), its role in DC accumulation was addressed
by using CCR6-deficient (CCR6º/º) mice. In agreement
with a previous report (Cook et al., 2000), we observed
that CCR6 is not involved in maintenance or self renewal
of epithelial tissue DC at the steady-state, as CCR6º/º
and wild-type (wt) mice harbored similar densities of
MHC class II+ DC in dermis or epithelium that were not
affected by injection of PBS (data not shown) or topical
application of acetone and oil that were used as control
vehicles (Figure 3C). More importantly, DNFB or NP
immunization via buccal mucosa (Figures 3C–3E) or
skin (data not shown) was totally unable to promote
DC accumulation in CCR6º/º mice. Thus, Ags triggering
of local CCL20 production in epithelial tissues pro-
motes local accumulation of DCs via a CCR6-dependent
mechanism.CCR6/CCL20 Is Required for CD8+ T Cell
Crosspriming Induced by DNFB or NP
We previously documented that DNFB-specific cyto-
toxic CD8+ T cells, induced by transepithelial skin or
buccal immunization, mediate contact hypersensitivity
(CHS) responses (Desvignes et al., 1998; Kehren et al.,
1999). Hapten-specific IFNg-producing CD8+ T cells can
be efficiently primed in C57BL/6 mice after cutanenous
immunization with doses of DNFB down to 0.1% (Fig-
ure 4A). Interestingly, CCR6 deficiency impaired hap-
ten-specific response, especially at suboptimal doses
of DNFB, and only CCR6-sufficient mice were primed
at the lowest dose of 0.1% DNFB. These findings dem-
onstrate that CCR6 is critical for priming of hapten-
specific CD8+ T cells with infra-optimal doses of Ag,
which most likely requires its local uptake by DCs.
We reasoned that CCR6-mediated DC recruitment
into epithelial tissues might be a prerequisite for priming
of CD8+ CTL against innocuous protein Ag. To test this
hypothesis, we used OVA as a prototype of poorly
immunogenic protein and exploited the adjuvant prop-
erties of DNFB and NP, which are both capable of
Immunity
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cal mucosa or skin (Figure 4 and N.E., M.L.B., and D.K.,
unpublished data). As expected, immunization with 1
mg of OVA alone was poorly efficient at generating
OVA-specific IFNg-producing CD8+ T cells (Figure 4B).
Alternatively, OVA+DNFB immunization via either buc-
cal mucosa (Figure 4B) or skin (Figure 4C) generated
a significant frequency of functional OVA-specific CD8+
CTL effectors as demonstrated both by IFNg ELISPOT
and in vivo CTL assays (Figure 4D). Interestingly,
DNFB can adjuvant OVA-specific CD8+ CTL responses
in the absence of CD4+ T cell help, as demonstrated
by using I-Ab deficient mice (see Figure S1 in the Sup-
plemental Data available with this article online). Com-
parable results were obtained with doses of OVA down
to 100 mg per mouse (data not shown). Likewise, buccal
Figure 2. Circulating DC Precursors Are Recruited to the Skin and
Contribute to LC Accumulation
(A) Epidermal cell suspensions from ear skin were prepared six
hours after painting with DNFB or vehicle alone, and hematopoietic
cells (CD45+) were analyzed for the expression of CD11b and Gr1.
Results are representative of three independent experiments.
(B) The ears of CD45.2/CD45.1 chimeric mice were painted with
DNFB or vehicle alone and analyzed 6 hr later. Histogram plots
show expression of CD45.2 (donor) on gated blood CD11b+ PBMCs,
MHC II+ dermal cells, and MHC II+ epidermal DCs. The percentage of
CD45.2+ cells is indicated. These data are representative of two in-
dependent experiments.immunization with NP+OVA generated OVA-specific
IFNg-producing CD8+ effector T cells (Figure 4E). Re-
markably, the adjuvant-dependent, OVA-specific CD8+
T cell priming was critically dependent on CCR6, inso-
much as DNFB+OVA or NP+OVA immunization was un-
able to induce significant OVA-specific class I-restricted
CD8+ T cell priming in CCR6º/º mice. In addition, immuni-
zation with OVA+NP in the presence of a neutralizing
anti-CCL20 Ab strongly reduced the frequency of
SIINFEKL-specific IFNg-producing CD8+ T cells, to
a level similar to that observed in CCR6º/º mice (Fig-
ure 4E). These findings demonstrate that the CCR6/
CCL20 pathway dictates successful crosspriming of
CD8+ CTL after transdermal immunization.
Most Adjuvants Require CCR6 to Induce CD8+
T Cell Crosspriming
We then examined whether the need for CCR6 could be
generalized to other CD8+ T cell adjuvants. Cholera toxin
(CT) and Flagellin (FliC) from Salmonella, two classical
mucosal adjuvants (Anjuere et al., 2004; Didierlaurent
et al., 2004) that similarly to DNFB and NP induce DC re-
cruitment into epithelia by triggering CCL20 production
(Anjuere et al., 2004; Sierro et al., 2001), also promoted
generation of OVA-specific CD8+ T cell effectors less ef-
ficiently in CCR6º/º mice than in wt mice (Figures 5A and
5B). Likewise, poly(I:C) (especially at low doses) ex-
hibited a CCR6-dependent CD8 adjuvant effect (Fig-
ure 5C). In contrast, CpG ODN did not require CCR6 to
promote CD8+ T cell priming (Figure 5D). Thus, efficient
CD8+ T cell priming with most adjuvants, but not CpG
ODN, critically depends on CCR6 expression.
Transfer of Gr1+ Monocytes Restores CD8+ T Cell
Crosspriming in CCR6-Deficient Mice
The above results suggest that epithelial delivery of ad-
juvants, by promoting the recruitment of circulating DC
precursors, allows for CD8+ T cell crosspriming against
the soluble coadministrated protein Ag and that this pro-
cess requires a functional CCR6/CCL20 pathway. Thus,
we tested whether adoptive transfer of blood DC precur-
sors at the time of OVA+DNFB cutaneous immunization
was sufficient to restore efficient OVA-specific CD8+
T cell response in CCR6-deficient mice. Remarkably,
CCR6+, but not CCR62, blood myeloid cells fully re-
stored the functional defect in CCR6º/º mice, resulting
in a frequency of OVA-specific IFNg-producing CD8+
T cells comparable to that of wt mice (Figure 6A). Mye-
loid mononuclear cells contain CD115+ monocytes and
CD11c+ cells (Figures S2 and S3A), which can both dif-
ferentiate into DCs in vivo (del Hoyo et al., 2002; Geiss-
mann et al., 2003; Randolph et al., 1999). Importantly,
the rescuing effect was restricted to CD115+ blood
monocytes (Figure S3B) and appeared as a hallmark of
Gr1+ monocytes (Figure 6B), a subset of monocytes
that has been shown to preferentially home to inflamed
tissues (Geissmann et al., 2003; Sunderkotter et al.,
2004), including DNFB-painted skin (Figure 2A). Interest-
ingly, transfer of monocytes by intravenous injection or
intradermal injection at the site of immunization similarly
restored CD8+ T cell priming (Figure 6C). Altogether,
these data demonstrate that CCR6-sufficient Gr1+
monocytes, which are rapidly mobilized to the site of
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195Figure 3. DC Accumulation Is Associated
with Increased CCL20 Production and Is
Dependent on CCR6
(A and B) RT-PCR analysis of CCL20 expres-
sion in the buccal mucosa 30 min or 2 hr after
NP injection (A) or topical application of DNFB
(B). Primers for b2m (A) and HPRT (B) were
used as controls.
(C) Staining for MHC class II was conducted
on sections of buccal mucosa of B6 ([C], up-
per) and CCR6º/º ([C], lower) mice after DNFB
(2 and 6 hr) or NP (2 hr) immunization. Final
magnification was 3400.
(D and E) Semiquantitative analysis of MHC
class II+ cells in the lamina propria (D) and
epithelium (E) of B6 (white bars) and CCR6º/º
(black bars) mice. Results are expressed as
the number of class II+ cells per square milli-
meter of tissue (*p < 0.01; NS, not significant).
Each dot represents the mean of four fields
in four sections in one buccal mucosa; each
histogram bar represents mean values of
three to six mice per group.cutaneous immunization, play a critical role in CD8+
T cell crosspriming.
H2-Kbm1 Monocytes Failed to Restore CD8+ T Cell
Crosspriming in CCR6-Deficient Mice
To determine whether monocytes need to present the
Ag to CD8+ T cells to allow efficient in vivo priming, sim-
ilar transfer experiments were performed with mono-
cytes purified from H2-Kbm1 mice. These mice have
mutated Kb MHC class I molecules that alter the presen-
tation of the dominant SIINFEKL OVA peptide and thus
prevent CD8+ T cell priming (Nikolic-Zugic and Carbone,
1990). As shown in Figure 6D, adoptive transfer of blood
myeloid cells from H2-Kbm1 mice into CCR6º/º H2-Kb re-
cipients poorly ameliorated the efficacy of OVA+DNFB
immunization as compared to the transfer of monocytes
expressing functional MHC class I molecules. This dem-
onstrates that presentation of the Ag to T cells by the
progeny of monocytes represents a critical step for
CD8+ T cell crosspriming.
Clodronate Liposomes Impair CD8+
T Cell Crosspriming
To further confirm the contribution of monocytes to the
induction of CD8+ T cell crosspriming, we analyzed the
consequences of clodronate (clo-lipo) injection 24 hr
prior to OVA+DNFB immunization in B6 mice. Suchtreatment resulted in the transient depletion of >96%
of circulating monocytes for 48 hr (Sunderkotter et al.,
2004 and Figure 7A). As depicted in Figure 7B, clo-lipo
treatment strongly impaired OVA-specific CD8+ T prim-
ing. Thus, the absence of circulating monocytes at the
time of immunization correlates with a reduced capacity
to initiate a CD8 response.
Discussion
Priming of specific CD8+ effector T cells after immuniza-
tion with soluble proteins via mucosa or skin may criti-
cally depend on the number, origin and function of DC
subsets available at the site of immunization, their ac-
cess to sufficient amounts of Ag, and their migratory
capacity. This study demonstrates that DCs, newly re-
cruited into epithelial tissues by adjuvants, are responsi-
ble for efficient in vivo crosspriming of CD8+ cytotoxic
T cells to a coadministered protein Ag and highlights
the crucial role played by the CCR6/CCL20 pathway in
this process.
We previously documented that the proinflammatory
hapten DNFB and measles virus NP are two powerful
CD8+ T cell immunogens (Etchart et al., 2001; Kehren
et al., 1999) that share the remarkable property of trig-
gering rapid, transient, and local increase of MHC II+
cells when administrated via pluristratified epithelia
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demonstrate that most of these cells, which accumulate
at the dermo-epithelial junction and in the suprabasal
layer of the epithelium, are MHC class II+CD11c+ mye-
loid DCs and include both dermal DCs and epithelial
Langerin+ DCs. By using bone marrow chimeras, Merad
et al. (2002) demonstrated that under steady-state
conditions, LCs are constantly renewed in the skin inde-
pendently of circulating precursors, whereas, after UV-
induced inflammation, LCs are replaced by blood-borne
LC progenitors. By using the same approach, we dem-
onstrated that rapid mobilization of circulating DC pre-
cursors into epithelial tissues significantly contributes
to LC accumulation at the site of DNFB immunization.
DC accumulation was first detected in dermal papillas,
a highly vascularized area, further arguing for a contribu-
tion of cells recruited from blood. Indeed, Gr1+ mono-
Figure 4. Critical Role of CCR6/CCL20 Interaction for Induction of
Ag-Specific IFNg-Producing CD8+ CTL
(A) B6 (white bars) or CCR6º/º mice (black bars) were painted on the
shaved abdominal skin with various doses of DNFB or vehicle alone.
The frequency of hapten-specific IFNg-producing CD8+ T cells was
determined 5 days later in skin draining lymph nodes.
(B–E) B6 (white bars), CCR6º/º (black bars), or anti-CCL20-treated B6
mice (gray bars) were immunized with either OVA (1 mg) + DNFB
(0.5%) administered via the buccal mucosa (B and D) or the ear skin
(C), or OVA (1 mg) +NP (30 mg) delivered via the buccal mucosa (E).
(B and C) Mean frequency of OVA-specific IFNg SFC in unfractio-
nated or CD8+-depleted draining lymph node cells. No IFNg-SFC
was observed when cells were incubated without SIINFEKL.
(D) In vivo OVA-specific CTL response was determined in draining
LN as described in the Experimental Procedures. Results are ex-
pressed as the mean percentage of OVA-specific cytotoxicity 6SD.
(E) Frequency of OVA-specific IFNgCD8+ SFC was determined in the
spleen. Data are representative of five experiments with three mice
per group.cytes, the most abundant blood DC precursors (Geiss-
mann et al., 2003), are rapidly mobilized to the skin
after DNFB immunization. This is consistent with other
studies demonstrating that Gr1+ blood monocytes rap-
idly extravasate into inflamed tissues and subsequently
differentiate into cells with features of DC (Geissmann
et al., 2003; Qu et al., 2004; Sunderkotter et al., 2004).
Thus, although recruitment of tissue-resident DCs from
adjacent skin areas likely occurs after immunization, ex-
travasation of blood precursors, including Gr1+ mono-
cytes, in the dermis or lamina propria significantly con-
tributes to DC accumulation at the site of immunization.
Extravasation of blood leukocytes into epithelial tis-
sues and their further migration within the dermal and
epidermal compartments is governed by local gradients
of chemokines. The epithelial tissue chemokine CCL20
has the capacity to induce in vitro chemotaxis of imma-
ture DCs, including monocyte-derived DCs, LCs, and
LC-committed progenitors (Dieu-Nosjean et al., 2000;
Yang et al., 1999), via binding to its unique receptor
CCR6 (Cook et al., 2000). At the steady-state, CCR6/
CCL20 is dispensable for homing and renewal of DCs
into pluristratified epithelial tissues such as skin (Cook
et al., 2000) and buccal mucosa (this study). Alterna-
tively, CCL20 could recruit immature DCs into epithelia
Figure 5. Most Adjuvants Require CCR6 Expression to Induce CD8+
T Cell Priming
B6 (white bars) or CCR6º/º (black bars) mice were immunized via the
buccal mucosa with OVA+PBS (A–C), OVA+CT (A), OVA+FliC (B),
OVA+poly(I:C) (C), OVA+CpG ODN1668, or OVA+control-ODN1720
(D). Frequency of OVA-specific IFNg-SFC in unfractionated draining
lymph nodes (A, C, and D) and in purified spleen CD8+ T cells (B). Re-
sults are representative of two (CT, FliC and CpG ODN) to three
(poly[I:C]) experiments with three mice per group.
DC Recruitment in Epithelia and CD8 T Cell Priming
197Figure 6. Transfer of CCR6+ Blood Gr1+
Monocytes Restores OVA-Specific CD8+
T Cell Priming in CCR6º/º Recipients
CCR6º/º mice received an intravenous (A–D)
or intradermal (C) transfer of enriched blood
monocytes from B6 (A, C, and D), CCR6º/º
(A), or H-2Kbm1 mice (D) or of purified Gr1+
or Gr12 CD115+ monocytes from B6 mice
(B). Mice were immunized with OVA alone
(white bars) or OVA+DNFB (gray bars) via
the ear skin, and the frequency of OVA-spe-
cific IFNg SFC in draining lymph nodes was
determined. No IFNg-SFC was observed
when cells were incubated without SIINFEKL.
All experiments, which included three mice
per group, were performed at least twice
with similar results.during inflammatory conditions such as in the cases of
psoriasis (Dieu-Nosjean et al., 2000) and graft-versus-
host disease (Merad et al., 2004). Our finding that adju-
vant-induced DC recruitment is observed in wt, but not
in CCR6º/º mice, provides in vivo evidence in a physiolog-
ical setting that inflammation caused by transepithelial
(DNFB) or transdermal (NP) immunization induces
local CCL20 secretion and promotes CCR6-mediated
DC chemotaxis into epithelial tissues. The fact that nei-
ther circulating DCs nor monocytes respond to CCL20 in
vitro (Vanbervliet et al., 2002) and that monocytes do not
express significant levels of CCR6 (Geissmann et al.,
2003) makes it unlikely that CCR6-mediated chemotaxis
dictates extravasation of blood DC or DC-precursors
into the dermis or lamina propria. Most likely, a first set
of chemokines, such as MCPs, promotes extravasation
Figure 7. Injection of Clodronate Liposomes Impairs OVA-Specific
CD8+ T Cell Priming in B6 Mice
B6 mice were injected intravenously with clo-lipo 24 hr prior to im-
munization with OVA+DNFB via the ear skin.
(A) Analysis of CD11b and CD115 expression on PBMCs in unteated
or clo-lipo-injected mice reveals nearly complete absence of mono-
cytes in blood 24 hr after injection.
(B) Frequency of OVA-specific IFNg SFC in draining lymph nodes.
No IFNg-SFC was observed in mice immunized with OVA alone.
These data are representative of two independent experiments
with three mice per group.of DC precursors into the dermis, and CCL20 subse-
quently allows recruited cells to further navigate within
the tissue and possibly reach the epidermis (Vanbervliet
et al., 2002). In this scenario, CCR6 expression by neo-
recruited DC precursors might be induced by locally
produced factors and/or by the transendothelial migra-
tion process. This hypothesis is supported by studies
showing that although transendothelial migration initi-
ates monocyte differentiation into DCs, full acquisition
of DC markers and functions requires additional signals
(Randolph et al., 1998). We propose from our data that
CCR6-mediated chemotaxis allows the nascent mono-
cyte-derived DCs to gain access to cytokines, including
GM-CSF, IL-4, TNFa, IL-15, and TGF-b, produced by
activated dermal mast cells and epithelial cells, which
favor their differentiation into bona fide DCs (Chomarat
et al., 2003; Mohamadzadeh et al., 2001). It is also pos-
sible that CCR6 engagement by CCL20 might directly
contribute to DC differentiation, as was recently demon-
strated for CCR8 (Qu et al., 2004).
DC accumulation in epithelial tissues has been re-
ported after mucosal or skin delivery of microbial agents
(McWilliam et al., 1996; Zhao et al., 2003), components
thereof (Anjuere et al., 2004; Etchart et al., 2001), and
proinflammatory haptens (Desvignes et al., 1998), yet
contribution of this process to the induction of efficient
T cell priming after transepithelial or transmucosal im-
munization has not so far been recognized. Our findings
clearly demonstrate that local DC recruitment plays
a critical role for CD8+ T cell crosspriming either against
DNFB used as an immunogen or against the innocuous
OVA protein Ag combined with DNFB or NP as adju-
vants. This conclusion is supported by the observation
that CCR6-deficient mice, which are unable to recruit DC
at the site of immunization, failed to generate hapten-
specific CD8+ effectors at a suboptimal dose of Ag. In
addition, CD8+ T cell priming in response to local immu-
nization with the innocuous protein OVA,witheitherDNFB
or NP as an adjuvant, critically depended on CCR6.
Finally,generationofOVA-specific IFNg-producingCD8+
CTL effectors was dramatically impaired both in CCR6º/º
mice and in wt mice that received a neutralizing anti-
CCL20 Ab together with the immunogen.
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circulating monocytes and their progeny in CCR6-
dependent CD8+ T cell priming. First, adoptive or local
transfer of blood monocytes from wt (but not CCR6º/º)
mice was sufficient to fully rescue the OVA-specific
CD8 response in CCR6º/º mice. Second, in vivo depletion
of circulating monocytes before immunization strongly
impaired CD8+ T cell crosspriming in normal mice. Third,
the capacity of monocytes to restore CD8+ T cell priming
was confined to the subset of Gr1+ monocytes previ-
ously reported to home to inflamed tissues (Geissmann
et al., 2003; Sunderkotter et al., 2004), including skin
(Qu et al., 2004), and to differentiate into DCs (Randolph
et al., 1999). Finally, Gr1+ monocytes are rapidly re-
cruited into the skin at the site of (DNFB) immunization.
Thus, although we cannot formally exclude that circulat-
ing monocytes may directly differentiate into lymph
node DCs, our findings strongly support that monocytes
recruited by adjuvants at the site of immunization give
rise to immunostimulatory DCs that are required for suc-
cessful CD8+ T cell crosspriming.
An important issue with respect to vaccine develop-
ment is whether the need for newly recruited DCs for ef-
ficient CD8+ T cell priming can be generalized to conven-
tional adjuvants. Interestingly, we found that both CT
and FliC, which share with DNFB and NP the ability to re-
cruit DCs into epithelia via CCR6 (Anjuere et al., 2004; Si-
erro et al., 2001), induce priming of OVA-specific CD8+
T cells by a mechanism that is at least partly dependent
on CCR6. Titrating poly(I:C), but not CpG ODN, also re-
vealed a window of doses at which CCR6/CCL20 is re-
quired for CD8+ T cell crosspriming. That CpG acts inde-
pendently of CCR6 indicates that this type of adjuvant
either bypasses the need for monocyte recruitment at
the immunization site or triggers alternative pathways
of DC recruitment. It is thus tempting to speculate that
depending on the nature and dose of the adjuvant used,
distinct subsets of DCs may be involved in the induction
of CD8 responses (Figure S4). The finding that B6, but
not H-2Kbm1, monocytes harboring nonfunctional mu-
tated MHC class I molecules restored CD8+ T cell cross-
priming in CCR6-deficient mice strongly supports the
hypothesis that direct Ag presentation by newly re-
cruited monocyte-derived DCs to naive CD8+ T cells is
instrumental for CCR6-dependent CD8+ T cell cross-
priming. Alternatively, CpG, by inducing functional acti-
vation of LN DCs (Shah et al., 2003), may promote pre-
sentation to CD8+ T cells of even small amounts of free
Ag that drain from epithelial tissues into the draining
lymph nodes (Figure S4).
There is increasing evidence against a prominent role
of LC in T cell priming induced by mucosal or cutaneous
immunization or infection (Allan et al., 2003; Kamath
et al., 2002; Kaplan et al., 2005; Kissenpfennig et al.,
2005; Ritter et al., 2004; Zhao et al., 2003), and some
authors propose that dermal or interstitial DCs might in-
deed constitute the key immunostimulatory APC (Itano
et al., 2003; Kissenpfennig et al., 2005; Zhao et al.,
2003). The present study identifies the progeny of re-
cruited monocytes as the critical APC for inducing
T cell priming, at least in the case of CD8+ T cells. It is un-
likely that recruited cells simply add to the pool of resi-
dent DCs leading to an increased number of APC in the
draining lymph nodes. Alternatively, it may be postu-lated that monocytes recruited from blood provide a
source of freshly differentiating DCs able to respond
better to danger signals than terminally differentiated
resident DCs that have experienced the immunosup-
pressive tissue microenvironment (rich in IL-10 and
TGFb). In addition, as demonstrated for CCR5 (Aliberti
et al., 2000), CCR6 engagement may not solely be in-
volved in DC chemotaxis but could also possibly favor
their subsequent maturation and/or immunolostimula-
tory function.
The present study demonstrates that blood-derived
myeloid DCs freshly recruited into epithelial tissues are
essential for successful priming of CD8+ CTL against
an inert protein. This finding may have important impli-
cations both for anti-infectious and antitumor vaccine
development. We propose that selection of molecules
with the dual capacity to induce local proinflammatory
cytokines and CCL20 production in epithelial tissues in
vivo should be most relevant to the design of mucosal
or skin vaccines.
Experimental Procedures
Mice
C57BL/6 female mice were purchased from Charles River Laborato-
ries (L’Arbresle, France). CCR6º/º mice (Cook et al., 2000) on the B6
background, C57BL/6-Ly5a, and H-2Kbm1 mice were bred at the
institute’s animal facility (Plateau de Biologie Expe´rimentale de la
Souris-Ecole Normale Supe´rieure de Lyon) under pathogen-free
conditions. For all experiments, 4- to 10-week-old mice were used.
Experiments have been approved by the Comite´ Regional d’Ethique
pour l’Expe´rimentation Animale.
Transplantation of Congenic Bone Marrow Cells
Seven- to eight-week-old recipient CD45.1+ C57Bl/6 mice were le-
thally irradiated (10 Gray) and were reconstituted by intravenous in-
jection of 8 3 106 bone marrow cells isolated from CD45.2+ mice.
Eight weeks after transplantation, mice were ear sensitized with
DNFB (Sigma-Aldrich, St. Quentin Fallavier, France). Six hr after im-
munization, ears were split into dorsal and ventral halves and incu-
bated for 45 min at 37ºC with 0.25% trypsin in PBS. Epidermal and
dermal sheets were separated and cut into small pieces. Dermal
fragments were further incubated for 60 min at 37ºC with 1000 U/ml
Collagenase IA (Sigma), 1000 U/ml Hyaluronidase (Sigma), and 200
U/ml DNase I (Roche Diagnostics, Mannheim, Germany). Peripheral
blood was harvested by cardiac puncture. PBMCs were isolated by
Lympholyte M gradient, and residual red blood cells were lysed with
0.83% NH4Cl. Cells were incubated with 2.4G2 hybridoma superna-
tant to block Fcg receptors and then stained with various combina-
tions of the following anti-mouse antibodies (BD Pharmingen): FITC
anti-I-Ab (2G9), PE anti-I-Ab (M5/114.15.2), PE anti-CD45.1 (A20),
PerCP-Cy5.5 anti-CD11b Ab (M1/70), and biotinylated anti-CD45.2
(104). Immunofluorescence was analyzed on a FACScalibur flow cy-
tometer with CellQuest software (Becton Dickinson).
Immunizations and Ab Treatment
Mice under pentobarbital anesthesia were injected intradermally,
either into the ear pinnae or the buccal mucosa (Etchart et al.,
2001), with 15 ml of PBS containing 0.1–1 mg of LPS-free ovalbumin
(OVA, Seikagaku corporation, Tokyo, Japan) alone or mixed with
either 30 mg recombinant NP produced in baculovirus (Etchart
et al., 2001), 1 mg CT (Sigma-Aldrich), 10 mg flagellin from Salmonella
enterica serovar typhimurium (FliC) prepared as previously de-
scribed (Sierro et al., 2001), 100 mg poly(I:C) (Sigma-Aldrich), or
50 mg of CpG ODN (50-TCCATGACGTTCCTGATGCT-30) or of control
ODN (50-TCCATGAGCTTCCTGATGCT-30) (MWG Biotech, France) as
adjuvants. Endotoxin levels in OVA and recombinant NP prepara-
tions were <0.1 U/mg as determined by the Limulus assay (Bio Whit-
taker, Walkersville, USA). Coimmunization with OVA+DNFB was car-
ried out the same way as OVA+NP immunization except that DNFB
(diluted at 0.5% in acetone:olive oil, 4:1 v/v) was painted onto the
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OVA administration. For certain experiments, mice received an intra-
dermal injection of 30 mg of neutralizing anti-mouse CCL20 poly-
clonal goat IgG Ab (R&D Systems) into the buccal mucosa just be-
fore coimmunization with OVA+NP. For certain experiments, 200 ml
of dichloromethylene-bisphosphonate liposomes (clo-lipo) were in-
jected i.v. 24 hr before immunization. Clodronate was a gift from
Roche (Mannheim, Germany) and was incorporated into liposomes
as described elsewhere (Van Rooijen and Sanders, 1994).
Histology and Immunohistochemistry
Buccal mucosae were deep frozen in Cryomount (Histolab, Go¨te-
borg, Sweden) for immunohistochemical analysis or paraffin-
embedded for histological staining with hematoxylin phloxin safran
(HPS). Cryostat sections (5 mm thick) were fixed in acetone for
20 min, rehydrated in PBS, and incubated for 1 hr at room tempera-
ture with specific antibodies including anti-MHC class II mAb
(CD311) (Etchart et al., 2001), anti-Langerin mAb (929 F3) kindly pro-
vided by Sem Saeland (Schering-Plough, Dardilly, France), anti-
CD11b mAb (M1/70), or overnight at 4ºC with anti-CD11c mAb
(N418). Specific binding was revealed by 30 min incubation with bio-
tinylated mouse adsorbed F(ab’)2 rabbit anti-rat IgG or goat anti-
hamster IgG antibodies (Vector Laboratories, Burlingame, CA) fol-
lowed by 30 min incubation with either streptavidin biotinylated
horse raddish peroxidase (HRP) (Amersham Biosciences, UK) or
with StreptABCComplex/HRP (Dako, Carpenteria, CA). Sections
were incubated with 3-amino-9-ethylcarbazole (Dako) and counter-
stained with hematoxylin (Dako). Cell counting was performed by
using an Axioscope microscope equipped with Zeiss Axiovision
software (Zeiss, Germany). Statistical analysis was performed by
using the Mann-Whitney-Wilcoxon nonparametric U test.
RT-PCR Analysis of CCL20 Gene Expression
Tissue samples were snap-frozen in liquid nitrogen and then
crushed into powder in a cold mortar over dry ice. For each sample,
the powder was resuspended in 700 ml 4 M guanidium thyocyanate,
25 mM Na citrate (pH 7.0), 0.5% Sarcosyl, and 0.1 M b-mercaptoe-
thanol solution (all from Sigma-Aldrich), and RNA was extracted
according to standard procedures (Chomczynski and Sacchi,
1987). Total RNA (5 mg) was pretreated with DNase I in the presence
of RNase inhibitor before reverse transcription into cDNAs by using
oligo(dT) primers (Pharmacia, Uppsala, Sweden) and the SuperScrip
kit. RT-PCR was performed with the AmpliTaq enzyme and buffer
(Perkin-Elmer, Paris, France), dNTPs at 0.8 mM, and 5% DMSO (final
concentration). Cycle conditions were 92ºC for 1 min, 60ºC for 2 min,
and 72ºC for 3 min for 28 to 35 cycles. The following primers were
used in this study: Beta-2 microglobulin, 30-TAGTCTTCCTGGTGC
TTGTC-50, 50-TGCTATTTCTTTCTGCGTGC-30; CCL20, 30-TGGGTA
CTGCTGGCTCAC-50, 50-CATCTTCTTGACTCTTAGGCT-30; HPRT,
30-GTAATGATCAGTCAACGGGGGAC-50, 50-CCAGCAAGCTTGCAA
CCTTAACCA-30.
IFNg ELISPOT Assay
Seven to ten days after immunization, graded numbers of unfraction-
ated or CD8+ T cells were incubated for 36 hr at 37ºC in nitrocellulose
96 well plates (MAHA 45, Millipore, Bedford, MA) coated with the
anti-IFNg R46A2 mAb (Pharmingen). Purified spleen CD8+ T cells
were incubated with irradiated splenocytes and 2 mM SIINFEKL or
0.4 mM DNBS. Total or CD8+ T cell-depleted lymph node cells
were stimulated with either 2 mM SIINFEKL or with 0.4 mM DNBS.
IFNg-producing cells were detected by using biotinylated anti-
IFNg Ab (XMG1.2, Pharmingen), streptavidin-alkaline phosphatase
(Roche Diagnostics), and 5-bromo-4-chloro-3-indolyl phosphate
(Sigma-Aldrich). The number of IFNg spot forming cells (SFC) was
counted in each well by using a binocular, and the results were ex-
pressed as the number of IFNg SFC per 106 cells.
In Vivo Cytotoxic Assay
CD8+ T cell cytotoxicity was assessed in vivo as previously de-
scribed (Aichele et al., 1997). Seven to ten days after immunization,
mice were injected i.v. with a mixture of 103 106 SIINFEKL-pulsed (2
mM) and 103 106 unpulsed spleen cells previously stained with a low
(0.5 mM) or high dose (5 mM) of CSFE (Molecular Probes, PooetGe-
bouw, The Netherlands), respectively. Twenty hours later, spleencells were collected, and 10,000 CFSE+ cells were analyzed on the
FACSCalibur (BD Biosciences). In vivo cytotoxicity was calculated
by determining the ratio of control targets/pulsed targets.
Adoptive Transfer of Monocytes
PBMCs were isolated by Lympholyte M (Cedarlane) gradient, and re-
sidual red blood cells were lysed with 0.83% NH4Cl. For transfer of
unfractionated myeloid PBMCs, CD4+, CD8+, and CD19+ cells were
depleted with a mix of anti-CD4, anti-CD8, and anti-CD19 mAb-
coated microbeads and LD columns (Miltenyi Biotec). Purified cells
contained 80%–90% CD11b+ cells including 40%–60% of mono-
cytes as determined by CD115 expression (Figure S2). Blood
CD115+Gr1+ and CD1152Gr12 monocytes were purified from CD3-
deficient mice by cell sorting with a FacsVantage (Becton Dickinson).
105 cells were injected either i.v. or i.d. at the site of immunization into
CCR6º/º mice 10 min before ear-skin immunization with OVA+DNFB.
Supplemental Data
Supplemental Data include four figures and can be found with this
article online at http://www.immunity.com/cgi/content/full/24/2/
191/DC1/.
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